Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Medtronic
Colorcon
AstraZeneca

Last Updated: May 26, 2022

Investigational Drug Information for BGB-290


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug BGB-290?

BGB-290 is an investigational drug.

There have been 104 clinical trials for BGB-290. The most recent clinical trial was a Phase 2 trial, which was initiated on November 2nd 2017.

The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Lung Neoplasms. The leading clinical trial sponsors are BeiGene, BeiGene USA, Inc., and National Cancer Institute (NCI).

There are five US patents protecting this investigational drug and fifty-two international patents.

Recent Clinical Trials for BGB-290
TitleSponsorPhase
Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid TumorsBeiGenePhase 1
Pamiparib in mCRPC With HRD or BRCA1/2 MutationSun Yat-sen UniversityPhase 2
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)Seoul National University Bundang HospitalPhase 2

See all BGB-290 clinical trials

Clinical Trial Summary for BGB-290

Top disease conditions for BGB-290
Top clinical trial sponsors for BGB-290

See all BGB-290 clinical trials

US Patents for BGB-290

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-290 See Plans and Pricing Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BEIGENE, LTD. (Grand Cayman, KY) See Plans and Pricing
BGB-290 See Plans and Pricing Process for preparing a PARP inhibitor, crystalline forms, and uses thereof BEIGENE, LTD. (Grand Cayman, KY) See Plans and Pricing
BGB-290 See Plans and Pricing Methods of treating acute kidney injury Mitobridge, Inc. (Cambridge, MA) See Plans and Pricing
BGB-290 See Plans and Pricing Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BeiGene, Ltd. (Grand Cayman, KY) See Plans and Pricing
BGB-290 See Plans and Pricing Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BeiGene, Ltd. (Grand Cayman, KY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BGB-290

Drugname Country Document Number Estimated Expiration Related US Patent
BGB-290 Australia AU2011384858 2031-12-31 See Plans and Pricing
BGB-290 Brazil BR112014012628 2031-12-31 See Plans and Pricing
BGB-290 Canada CA2856309 2031-12-31 See Plans and Pricing
BGB-290 China CN103703004 2031-12-31 See Plans and Pricing
BGB-290 China CN106220635 2031-12-31 See Plans and Pricing
BGB-290 Cyprus CY1119804 2031-12-31 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Medtronic
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.